Who are Envisia Therapeutics's investors?

Envisia Therapeutics's investors include Canaan Partners, New Enterprise Associates (NEA), Pappas Capital, +ND Capital, ARCH Venture Partners, Illumina Ventures, OMX Ventures.

How much funding has Envisia Therapeutics raised?

Envisia Therapeutics has disclosed $14.7M raised across 2 of its 3 known rounds.

Where is Envisia Therapeutics headquartered?

Envisia Therapeutics is headquartered in Morrisville, US.

Envisia Therapeutics

Morrisville, US · Founded 2013 · Delaware corporation · 7 known investors

Find your way into Envisia Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Envisia Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Develops novel ocular therapies.

Biotech

Founders & leadership

Ben YerxaPresident2015–2017Dr. Yerxa brings over 30 years of pharmaceutical and biotechnology leadership experience across ophthalmology, rare disease, and other therapeutic areas, including roles as a corporate officer at Inspire Pharmaceuticals and CEO of Foundation Fighting Blindness, where he oversaw drug discovery through commercialization, regulatory submissions, and technology licensing. He holds more than 50 U.S. patents and has contributed to the development of multiple drug candidates and approved therapeutics.

Eric LinsleyChief Financial Officer2015–2017Eric Linsley is Managing General Partner of BioInnovation Capital, overseeing the firm's North Carolina lab and life sciences investments. He previously served as Chief Financial Officer of TriPath Imaging, a medical device company acquired by Becton Dickinson in 2006, and before that at AutoCyte, which completed an IPO in 1997; he also spent over a decade at Pappas Ventures investing in therapeutics, diagnostics, and medical devices.

Board

Ed MathersBoard directorPartner at New Enterprise Associates (NEA)

Stephen Bloch Board directorCo-founder and Chief Executive Officer at EvolveImmune Therapeutics

Seth RudnickBoard directorInvestor at Canaan Partners

Neal FowlerBoard director

Adrienne GravesBoard director

Gary PhillipsBoard director

Investors · 7

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20Mvia Stephen Bloch · board

How we know: Canaan Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Ed Mathers · board

How we know: board seat on SEC Form D · Not right? Tell us

Pappas Capitallisted by Pappas CapitalDurham

How we know: Pappas Capital's portfolio page · Not right? Tell us

+ND CapitalreportedWoodside · $540K – $5.4M

How we know: funding news · Not right? Tell us

ARCH Venture PartnersreportedChicago · $50K – $250M

How we know: funding news · Not right? Tell us

Illumina VenturesreportedFoster City

How we know: funding news · Not right? Tell us

OMX VenturesreportedLincolnshire

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$14.7M disclosed across 2 of 3 rounds · 2015–2026

▶$10.1MraisedMar 2016 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

William YelleDirector
Gary PhillipsDirector
Ed MathersDirector
Adrienne GravesDirector
Neal FowlerDirector
Eric LinsleyExecutive Officer
Ben YerxaExecutive Officer
Stephen BlochDirector

Offering amount: $16.5M
Amount sold: $10.1M
Proceeds to insiders: $500K
First sale: Mar 2016
Incorporated: Corporation, Delaware, 2013
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.6MraisedOct 2015 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Ed MathersDirector
Adrienne GravesDirector
Stephen BlochDirector
Ben YerxaExecutive Officer
Gary PhillipsDirector
Seth RudnickDirector
Neal FowlerDirector
Eric LinsleyExecutive Officer

Offering amount: $5.1M
Amount sold: $4.6M
Proceeds to insiders: $500K
First sale: Oct 2015
Incorporated: Corporation, Delaware, 2013
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Envisia Therapeutics went on to found or lead other companies.

Stephen BlochDirectorFounded EvolveImmune Therapeutics +1 Christy ShafferExecutive OfficerFounded Opus Genetics

In the news

Envisia Therapeutics Secures $16.5 Million In Additional Series A Financingprnewswire.com · Mar 2016

Frequently asked questions

What does Envisia Therapeutics do?: Develops novel ocular therapies.
Who are Envisia Therapeutics's investors?: Envisia Therapeutics's investors include Canaan Partners, New Enterprise Associates (NEA), Pappas Capital, +ND Capital, ARCH Venture Partners, Illumina Ventures, OMX Ventures.
How much funding has Envisia Therapeutics raised?: Envisia Therapeutics has disclosed $14.7M raised across 2 of its 3 known rounds.
Where is Envisia Therapeutics headquartered?: Envisia Therapeutics is headquartered in Morrisville, US.